<unk>  is a sclerostin inhibitor that is FDA approved for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include arthralgia and headache.
Romosozumab
Evolocumab
Nebacumab
Ustekinumab
Burosumab
Sarilumab
Alirocumab
Dupilumab